Stimulant Duration Clock: Cardiovascular Monitoring Scheduler for ADHD Prescribing
A scheduling tool for doctors that sets blood pressure check-ups based on how long a patient has been taking ADHD meds.
An EHR/telehealth module that reads each patient's ADHD medication dispensation history and automatically generates a blood-pressure and cardiovascular-symptom monitoring schedule timed to the risk curve: tighter checks during the first 3 years of use, annual after, and stricter cadence for patients on higher doses.
Concept
A decision-support module embedded in the prescribing workflow of behavioral health clinics and telehealth psychiatry platforms. It computes two numbers from pharmacy dispensation records — cumulative years of ADHD medication use and mean daily dose (in defined daily doses, DDDs) — and converts them into a personalized cardiovascular monitoring calendar:
- Baseline: blood pressure, pulse, and cardiovascular/family history before or at initiation.
- Years 0–3: BP check every 6 months, because this is when per-year cardiovascular risk climbs fastest (~8% per additional year of use).
- After year 3: annual BP plus a brief cardiovascular symptom review, since risk stabilizes at a plateau (adjusted odds ratio ~1.23–1.27 vs. non-use).
- High-dose flag: patients averaging ≥1.5× the defined daily dose keep the 6-month cadence and get an annual "is this the lowest effective dose?" review, because risk accrues faster at higher doses (~5%/year at DDD >2 vs ~4% overall).
- Escalation: two elevated readings trigger a recommendation for ambulatory/home BP monitoring or cardiology referral.
- Age-aware: the same logic applies to pediatric (age 6+) and adult patients, since the underlying study found similar patterns in both groups; for children, BP percentile checks can be anchored to existing well-child visits.
The output is a documented monitoring plan per patient and a panel-level dashboard showing which patients on long-term medication are overdue for a cardiovascular check.
Why now
The Swedish national case-control study (278,027 individuals with ADHD aged 6–64; 10,388 with incident cardiovascular disease; up to 14 years of cumulative medication use) is the first large-scale quantification of how cardiovascular risk scales with duration of ADHD medication: each additional year of use is associated with a 4% increased CVD risk (AOR 1.04), rising fastest in the first 3 years (AOR 1.08 per year) and stabilizing at AOR 1.27 (3–5 years) and 1.23 (>5 years). Hypertension is the strongest signal (AOR 1.72 at 3–5 years; 1.80 beyond 5 years), and risk grows faster at higher mean doses (5%/year at DDD >2, statistically significant only at ≥1.5 DDD). The authors explicitly conclude that clinicians should "regularly and consistently monitor cardiovascular signs and symptoms throughout the course of treatment" — yet no standard, duration-triggered monitoring schedule exists. With an estimated 15.5 million U.S. adults carrying an ADHD diagnosis (6.0% of adults, 2023 NCHS data) and pharmacological treatment as the established standard of care for ADHD, long-term exposure is the norm, making an automated monitoring scheduler the direct operational translation of this evidence.
Written by GLM · 10 Oct 2026
AI assessment
A highly focused, evidence-backed clinical decision support tool that converts a specific cardiovascular risk curve into an automated monitoring schedule for ADHD clinics.
- Evidence strength 5/5
- The idea directly translates the specific AORs and time-based risk plateaus (0-3 years vs 3+ years) from a massive Swedish national study into a concrete clinical protocol.
- Market pull 4/5
- Large telehealth ADHD providers (e.g., Done, Talkiatry) face significant regulatory and liability pressure to standardize safety monitoring for stimulants.
- Novelty & moat 4/5
- While other catalog ideas focus on SUD screening or exercise, this is the first to operationalize the specific long-term cardiovascular risk duration curve.
- Feasibility 5/5
- The logic is a simple set of conditional triggers based on pharmacy data and dates, making it a low-complexity EHR integration.
- Wedge clarity 5/5
- The wedge is a single, sharp utility: an automated cardiovascular monitoring calendar for stimulant prescribers.
- Simplicity / focus 5/5
- It avoids 'platform' creep, focusing exclusively on one clinical risk factor and one specific output (the schedule).
Scored by Gemma 4 · 10 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
- Talkiatrycompany
A telehealth psychiatry platform with a large ADHD caseload; an automated duration-triggered cardiovascular monitoring module lets its psychiatrists document cardiovascular safety across thousands of stimulant patients without adding manual tracking burden.
- Kaiser Permanenteorganization
An integrated delivery system with a unified EHR (HealthConnect) containing both dispensation and diagnosis data, so the duration clock and overdue-check dashboard can be automated across its pediatric and adult ADHD populations.
- Done.company
A high-volume ADHD telehealth prescriber whose biggest clinical-liability gap is long-term safety monitoring; a codified, evidence-based CVD monitoring protocol directly strengthens and differentiates its standard of care.
- LifeStance Healthcompany
One of the largest outpatient mental health groups, with many prescribers managing long-term ADHD medication; a standardized monitoring scheduler turns an untracked risk into a documented, auditable workflow.
- ADHD Onlinecompany
A multi-state telehealth ADHD treatment provider that needs a defensible, systematic cardiovascular monitoring workflow for patients it manages remotely, often for years at a time.
Research it builds on
- Evidence-based pharmacological treatment options for ADHD in children and adolescentsKonstantin Mechler, Tobias Banaschewski, Sarah Hohmann et al. · 2021 · 296 citationsAll ideas from this paper →
- Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular DiseasesLe Zhang, Lin Li, Pontus Andell et al. · 2023 · 148 citationsAll ideas from this paper →
- Attention-Deficit/Hyperactivity Disorder Diagnosis, Treatment, and Telehealth Use in Adults — National Center for Health Statistics Rapid Surveys System, United States, October–November 2023Brooke S. Staley, Lara R. Robinson, Angelika Hartl Claussen et al. · 2024 · 87 citationsAll ideas from this paper →